The fee for ethical review of industry
sponsored studies is $1,000.00 and applies
only to research that receives its funding
from an industry sponsor (i.e.
pharmaceutical/medical devices company or an
agent thereof). The fee covers the
submission of the initial request for
ethical review, subsequent amendment and
renewal applications, as well as the
submission of serious and unexpected adverse
event reports in the case of clinical
trials.
Payment of the required fee, or a letter stating that the fee will follow and by
when, must accompany the Application for Research Ethics Review for all
industry-sponsored research. It is the responsibility of the Principal
Investigator to ensure that their sponsor is aware of this requirement and to
submit the cheque or letter at the time of the submission to the REB. The REB
will review the research only if the fee or a letter accompanies the
application.
Waiver Criteria
The fee is waived for:
1. Studies receiving a grant-in-aid (normally an investigator-initiated study
with partial funding-e.g. supply of drugs or devices or a very limited amount of
funding from an industry sponsor);
2. Studies that are funded by not-for-profit agencies;
3. Studies that receive internal grants either from RQHR-affiliated institutions
(including self-funded);
4. Studies funded by CIHR, NSERC, CHSRF, and NIH (including NIH Institutes),
and;
5. Studies without funding.
Mechanism for Submitting the Fee
For cheques sent to the REB office AFTER the submission of the initial
application: Accompany the cheque with a memo that identifies the study by
citing the Principal Investigator's name and the exact study title. Requests for
invoices sent to the REB office after an application is submitted, must include
the exact title of the research study and the Principal Investigator's name.
Requirements For Fee Refund
The fee will be totally refunded if the associated research study is withdrawn
prior to review. $500.00 of the fee amount will be non-refundable if the
associated research study is withdrawn after the review.
